Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Ozoralizumab (TS-152) in Methotrexate-Inadequate Response Rheumatoid Arthritis
jRCT2080223971Phase 3Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozoralizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Taisho Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223971.